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Abstract HIV/AIDS remains to be one of the killing
diseases of mankind. Host genetic response is one of the
factor which determine susceptibility to HIV and disease
progression to AIDS. The aim of the present study was to
evaluate the impact of ERCC2 Lyc751Gln (excision repair
cross complementing rodent repair deficiency, comple-
mentation group 2) polymorphism on HIV-1 susceptibility
and disease progression to AIDS, as this gene has been
reported to intervene in degrading retroviral cDNA before
it integrates with the host DNA. This case control study
included 300 HIV seropositive cases and an equal number
of HIV seronegative controls. DNA was isolated from the
blood samples of study subjects and genotyping of ERCC2
was conducted by polymerase chain reaction (PCR) and
restriction fragment length polymorphism (RFLP) method.
The Gln/Gln genotype showed a significant variation
between cases and controls (P = 0.047, OR 1.71, 95% CI
1.00–2.93), indicating a possible role of susceptibility in
reference to controls and disease progression when com-
pared within cases.
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Introduction
There was a total death of 2.1 million people by AIDS in the
year 2007 alone. Two and a half million people were newly
infected with HIV/AIDS in the same year. A total of
32.2 million people were living with HIV/AIDS worldwide
in 2007. Nevertheless, it is estimated that the overall number
of people living with HIV will increase in the coming years
as a result of the ongoing number of new infections each
year and the beneficial effects of more widely available
antiretroviral therapy. In Asia, an estimated 5 million (4.1–
6.2 million) people were living with HIV in 2007. The
number of new infections and people who died from AIDS-
related illnesses were comparatively equal in 2007 which is
380,000 (200,000–650,000) and 380,000 (270,000–
490,000) respectively. National HIV infection levels are
highest in South-East Asia. New HIV infections are also
increasing steadily, although at a much slower pace, in
populous countries such as Bangladesh and China. New
more accurate estimates indicate that approximately 2.5
million (2–3.1 million) people in India were living with
HIV in 2006, and that adult national HIV prevalence was
0.36%. Although the proportion of people living with HIV is
lower than previously estimated, India’s epidemic continues
to be substantial in terms of absolute numbers [1].
The role of host genetic factor in HIV susceptibility and
disease progression has been explained by a well-charac-
terized 32-bp deletion in the host cell chemokine receptor
CCR5 [2]. When HIV binds to host cells, it uses the CD4
receptor on the surface of host immune cells together with
a co receptor, mainly the CCR5 and CXCR4 chemokine
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receptors [3, 4]. Homozygous mutations for this 32-bp
deletion offer almost complete protection from HIV
infection through the formation of a truncated receptor
preventing viral entry [5–8], and heterozygous mutations
are associated with lower pre-AIDS viral loads and delayed
progression to AIDS [9–16].
ERCC2 (excision repair cross complementing rodent
repair deficiency, complementation group 2), also known
as Xeroderma Pigmentosum group D (XPD), encodes
ERCC2 protein which has a helicase activity and plays a
key role in nucleotide excision repair (NER) pathway [17].
Moreover, this gene appears to play a principal role in the
degradation of retroviral cDNA. This XPD-dependent
reduction of retroviral cDNA results in decreased suc-
cessful integration events of the proviral DNA [18].
Reverse transcription of retroviral RNA genomes produce a
double stranded linear cDNA molecule. A host degradation
system prevents a majority of the cDNA molecules from
completing the obligatory genomic integration necessary
for pathogenesis. Yoder et al. [18] demonstrated that the
human TFIIH complex proteins XPB (ERCC3) and XPD
(ERCC2) play a principal role in the degradation of ret-
roviral cDNA. They further explained that DNA repair-
deficient XPB and XPD mutant cell lines exhibit an
increase in transduction efficiency by both HIV and Mo-
loney murine leukemia virus-based retroviral vectors.
Nucleotide excision repair (NER) is a DNA damage
removal pathway that is conserved from E. coli to humans
and is triggered in response to specific types of DNA
damage [19].
Till date six exonic single nucleotide polymorphisms
(SNPs) have been reported in ERCC2, and of them, A ? C
polymorphism at codon 751 on exon 23 has been studied
most widely and reported to modulate cancer of different
types. This ERCC2 (db SNP no. rs13181) A ? C change
results in amino acid substitution from lysine to glutamine.
Thus, codon 751 variant leads to total rearrangement of the
electronic configuration of the amino acid [20, 21]. It has
been well established that the genetic disorder in the
nucleotide excision repair pathway results in a number of
diseases including cancer of different organs and HPV
[22].
Different cohort studies of HIV-1 infected subjects have
clearly indicated that the rates of progression of HIV dis-
ease may vary greatly among individuals. Although most
individuals infected with HIV develop AIDS within a
median period of 10 years, approximately 10% of HIV
infected subjects progress to AIDS within the first
2–3 years of seroconversion (rapid progressors), and
approximately 5–10% remain asymptomatic and have sta-
ble CD4/T lymphocyte counts 10 years after seroconver-
sion (nonprogressor) [23]. A growing body of evidence
suggests that host genetic factors play an important role
both in susceptibility to HIV infection and progression to
AIDS [24].
Among host factors that affect HIV disease progression
are age, gender, route of transmission, life stress and
genetic polymorphism of some genes such as CCR5,
CXCR4, HLA, CYP, SDF do play major role in affecting
disease progression from individual to individual [25–27].
The main aim of this study was to evaluate impact of
XPD Lyc751Gln polymorphism on individual susceptibility
to HIV-1 and its progression to AIDS in relation to other
factors that affect rate of disease progression. Specifically,
individual genetic differences in HIV disease progression
and ERCC2 gene were investigated in HIV seropositive
cases and role of this gene in respect to susceptibility was
compared with seronegative control participants.
Materials and methods
Study population
Written informed consent was obtained from all the cases
and controls. The study was carried out after obtaining
approval from the ethical committee of Postgraduate
Institute of Medical Education and Research, Chandigarh,
India. For this case- control study, peripheral blood sam-
ples (2–3 ml) were collected from 600 north Indian sub-
jects during December 2007 to October 2008. These
included HIV infected individuals (n = 300) from the
immune deficient clinic of the Post Graduate Institute of
Medical Education and Research (PGIMER), Chandigarh.
The control blood samples (n = 300) were also collected
from the same geographical area after they were confirmed
to be seronegative for HIV by ELISA I and II tests and free
from any other chronic illness. Inclusion criteria for cases
were being seropositive for HIV-1 infection before starting
HAART (Highly Active Anti Reteroviral therapy) and age
range 18–60. Those seropositive patient who did not give
written consent, age range less than 18 or greater than 60
and who did start HIV treatment were excluded from this
study. Similarly the inclusion criteria for controls were age
range 18–60 and being seronegative for HIV-1 test and
individuals without any chronic symptom of disease. The
exclusion criteria for controls was age range less than 18 or
greater than 60, being seropositive for HIV-1 test, any
symptom of chronic illness and failure to give written
consent. All controls were healthy with no symptoms of
disease. Detailed clinical data regarding age, sex, year of
infection, occupation, CD4 count, stage of disease and
route of transmission was obtained from the patients’
record.
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ERCC2 genotyping
Genomic DNA was extracted from peripheral blood by
proteinase K digestion and phenol–chloroform extraction.
Genomic DNA was used to genotype XPD Lys751Gln by
means of polymerase chain reaction (PCR) and restriction
fragment length polymorphism (RFLP) analysis. PCR was
performed in 25 ll reaction mixture, containing 50 ng of
genomic DNA 2 mM MgCl2, 0.04 mM deoxynucleotide
triphosphates, 1.0 U of Taq polymerase, and the Manu-
facturer’s buffer [20 mM Tris–HCl (pH 8.4) and 50 mM
KCl]. PCR condition was accomplished by initial dena-
turation at 94C for 4 min was followed by 30 cycles of
30 s at 94C, 30 s at 60C and 1 min at 72C, and then a
final extension step of 7 min at 72C. The 734 bp XPD
PCR products were amplified with the primers 50-CCTCTC
CCTTTCCTCTGTTC-30 (forward) and 50-GGTGAGGGG
GACATCT-30 (reverse). Twenty microliter of PCR product
(734 bp) (Fig. 1) was digested with 10 U of Pst I restric-
tion enzyme and 19 buffer supplied with the enzyme (New
England Bio labs, USA) at 37C overnight. The variant
allele revealed 646 bp fragment following digestion and
3% agarose gel electrophoresis, while the wild allele was
not able to be digested by Pst I [28] (Fig. 2).
Statistical analysis
Chi-square analysis was utilized to test the frequencies of
the genotype and alleles. Age, sex, occupation, transmis-
sion route, CD4 count, disease stage and opportunistic
disease infection were tabulated for cases. The association
between polymorphism of XPD gene with the risk of HIV
was estimated by computing odds ratio (OR) and 95%
confidence intervals (95% CI), using a multivariate logistic
regression analysis that included several variables such as
age, opportunistic infection, stage of HIV, route of trans-
mission and CD4 count. The statistical analysis was per-
formed using Epi-Info software (Epi-Info, version 3.5.1.
Center for Disease Control and Prevention, Atlanta, GA,
USA) and software SPSS version 11.5 (SPSS, Chicago,
IL). Significance was set at P \ 0.05.
Results
This study analyzed the role of XPD Lyc751Gln polymor-
phism in risk of HIV-1 susceptibility and progression to
AIDS in north Indian Population. The study included 300
cases and an equal number of controls. Although effort was
made to frequency-match cases and controls by age, cases
were younger in average than controls. However, there was
no significant difference in the mean age between cases
(mean ± SD, 35 ± 8) and controls (36 ± 10) (P [ 0.05).
There were more males in the study. Among cases, the
number of men was 193 (64.3%), and that of women it was
107 (35.7%). Similarly the number of men in controls was
195 (65%) and that of women it was 105 (35%).
Of the 300 HIV patients, 9% were at stage I of HIV,
18% were at stage II, and the remaining 24.3 and 48.7%
were at stages III and IV respectively. Percentage of dis-
ease stage on basis of sex is given in Table 1.
Among all the study subjects (cases), truck drivers
accounted for about 21.7% followed by farmers 18.3%,
labourers 8.7% and others working in different private and
public sectors accounted 21.7%. Almost all women were
house wives and they accounted for 29.6% of the
Fig. 1 PCR amplified product of XPD gene of HIV seropositive
subjects. Lane 8 100 bp DNA marker, lane 1–7 734 bp XPD PCR
product
Fig. 2 PCR-RFLP representative agarose gel of XPD (Pst I) digest
genotype analysis of HIV seropositive subjects. Lane 5 100 bp DNA
marker, lane 1, 3, 7, 8 Lyc/Gln 646 and 734 bp, lane 2 and 6 Lyc/Lyc
734 bp, lane 4 Gln/Gln 646 bp
Table 1 Study subjects (cases) and the stages of HIV AIDS
Stage Male Female Total
n % n % n %
I 18 9.3 9 8.4 27 9
II 32 16.6 22 20.6 54 18
III 48 24.9 25 23.3 73 24.3
IV 95 49.2 51 47.7 146 48.7
Total 193 100 107 100 300 100
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occupation share. Of all the women cases, only eight
belonged to the fourth category. Table 2 shows the cate-
gory of cases on the basis of occupation.
The transmission route of HIV among cases was mostly
of heterosexuality that accounted for 92.3% of the trans-
mission, which was followed by unknown and blood
transfusion accounting for 4.4 and 1.7% respectively.
Acquiring HIV during sharing of contaminated needle and
men who had sex with men (MSM) accounted for 1.3 and
0.3% respectively. Cases that belonged to the unknown
category were those involved in more than one possible
routes of transmission and did not exactly know the source
of their infection.
The percentage of the ERCC2 Lyc751Gln genotype
distribution for both cases and controls is given in
Table 3. Chi-square (v2) analysis was utilized to test the
Hardy Weinberg’s equilibrium, the study subjects were in
accordance with this equilibrium P [ 0.05. The per-
centage of the Lyc/Lyc genotype in controls was greater
(38.7%) as compared to cases (29.7%). The Lyc/Gln
genotype percentage was more in cases (53.6%) than in
controls (48.7%). The percentage of the Gln/Gln geno-
type was 16.7% in cases as compared to 12.7% in
controls. A significant variation existed among cases and
controls with respect to the variant Gln/Gln genotype
(P = 0.047, OR 1.71, 95% CI 1.00–2.93). The combined
Lyc/Gln ? Gln/Gln genotypes too showed a significant
variation in cases (P = 0.025, OR 1.49, 95% CI 1.05–
2.13). The stage of HIV and frequency of genotype at
each stage is given in Table 4. The staging was done by
physicians as per the WHO clinical staging of HIV
disease in adults and adolescents (Version 2006). Among
the total 300 study subjects, 219 were found to be at
stages III and IV. The mean CD 4 count was found to be
498, 384, 259 and 116 for stages I, II, III and IV
respectively. Statistically significant association was
observed between the heterozygous Lyc/Gln and variant
homozygous Gln/Gln genotypes and stage IV of HIV
(OR 1.72, 95% CI 1.06–2.81, P = 0.028 and OR 2.71,
95% CI 1.43–5.18, P = 0.0016) respectively indicating a
probable risk of accelerated disease progression. The
frequencies of the three genotype of ERCC2 were cor-
related with time of disease progression. Table 5 shows
the distribution of the three genotypes in respect to time
of disease progression for each stage. 4.48 folds of
increased risk towards accelerated disease progression
was observed between Gln/Gln genotype in 3–5 years of
seroconvertors at stage IV of HIV (OR 4.48, 95% CI
1.99–10.18, P = 0.0000979).
Table 2 Study subjects (cases) and their occupation
Occupation Male Female Total
n % n % n %
Labourer 20 10.4 6 5.6 26 8.7
Farmer 51 26.4 4 3.7 55 18.3
Truck driver 65 33.7 – – 65 21.7
House wife – – 89 83.2 89 29.6
Others 57 29.5 8 7.5 65 21.7
Total 193 100 107 100 300 100
Table 3 Genotype and allele frequency of ERCC2 among study
subjects
Genotype Cases Controls P value OR (95% CI)
n % n %
Lyc/Lyc 89 29.7 116 38.7 1 (Ref.)
Lyc/Gln 161 53.6 146 48.7 0.055 1.44 (0.99–2.08)
Gln/Gln 50 16.7 38 12.7 0.047a 1.71 (1.00–2.93)
Lyc/Gln ? Gln/
Gln
211 70.3 184 61.4 0.025b 1.49 (1.05–2.13)
Allele = Lyc 339 56.5 378 63
Gln 261 43.5 222 37 0.025c 1.31 (1.03–1.66)
OR was calculated by EPI-Info. version 3.5.1. (Center for Disease
Control and Prevention)
CI confident interval, OR odds ratio, Ref reference
a, b, c P \ 0.05
Table 4 Distribution of ERCC2 genotype in respect to each stage of
HIV
Stages of
HIV
Genotypes of
XPD
n/c OR (95% CI) P
I Lyc/Lyc 9/116 1.0 Ref. 1.0 Ref.
Lyc/Gln 12/146 1.06 (0.40–2.84) 0.91
Gln/Gln 6/38 1.89 (0.71–5.02) 0.22
II Lyc/Lyc 22/116 1.0 Ref. 1.0
Lcy/Gln 29/146 1.05 (0.55–2.0) 0.45
Gln/Gln 3/38 0.46 (0.41–1.46) 0.25
III Lyc/Lyc 22/116 1.0 Ref. 1.0
Lcy/Gln 42/146 1.52 (0.83–2.79) 0.19
Gln/Gln 9/38 1.25 (0.48–3.16) 0.77
IV Lyc/Lyc 36/116 1.0 Ref. 1.0
Lcy/Gln 78/146 1.72 (1.06–2.81) 0.028a
Gln/Gln 32/38 2.71 (1.43–5.18) 0.0016b
OR was calculated by EPI-Info version 3.5.1. (Center for Disease
Control and Prevention)
n/c genotype at particular stage to number of control for the same
genotype, OR odds ratio, 95% CI confidence interval
P value \ 0.05 significant
a, b P \ 0.05
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Discussion
Apart from the NER pathway for repairing adducted DNA,
the ERCC2 gene is involved in degradation of viral cDNA,
polymorphism in this gene might have reduced effect on
viral cDNA degradation, whereby viral replication would
be successful and reduces CD4 count to promote HIV
disease progression to AIDS. This is the first study that has
attempted to find out the association of ERCC2 Lyc751Gln
polymorphism with HIV/AIDS disease progression. In fact
it has been reported that the presence of variant allele of
this gene is associated with an increased risk of cancers
such as melanoma [29], prostate [30], bladder [31],
oesophagus [32] among others. However, conflicting
reports have also been available with respect to different
cancer types: bladder [33], breast [34, 35] and lung [36].
The Gln/Gln genotype frequency showed significant
variation between cases and controls suggesting a possible
role of disease susceptibility in cases. Moreover, this
genotype was found to be associated with rapid disease
progression in 3–5 years seroconvertor category.
The present finding indicated that the Gln/Gln genotype
has impact on HIV-1 susceptibility and play role in disease
progression to AIDS, the Lyc/Gln genotype too showed
association with stage and risk of accelerated disease pro-
gression. Yoder et al. [18] indicated that XPD and XPB
mutant cells have high transduction of viral cDNA indi-
cating reduced role of these two mutated genes in
degrading viral cDNA. It is consistent with the present
study where the variant Gln/Gln genotype of ERCC2 gene
was significantly associated with disease susceptibility and
progression due to the reduced role of the ERCC2 protein
in viral cDNA degradation, thereby, increasing the pool of
available cDNA for integration and ultimately promoting
low immune response to opportunistic infection. Actually
this finding needs to be confirmed with large cohort study
by including other disease progression measures like viral
load, and other clinical and molecular markers. Likewise,
the physiological process, how the variant genotype facil-
itates susceptibility and disease progression in HIV infec-
tion needs to be explained by testing in vitro experiments,
though it is ascertained that the ERCC2 Lyc751Gln poly-
morphism is predicted to affect protein function in nucle-
otide excision repairing pathway [21]. In addition, it has
been observed that mutations in the XPD gene can diminish
the activity of TFIIH complexes giving rise to repair
defects, transcription defects, and abnormal responses to
apoptosis. Because XPD is important in multiple cellular
tasks and rare XPD mutations results in genetic diseases
XPD polymorphism may operate as genetic susceptibility
factor [37]. Furthermore, this gene may also participate in
other regulatory cellular processes including DNA repli-
cation and basal transcription [38], cell cycle progression
[39], and P53 mediated apoptosis [40, 41]. Due to this vital
role of the XPD gene in the basic physiology of the cell, the
Gln/Gln genotype might be playing a significant role for
HIV susceptibility and disease progression. One of the
drawbacks of this study was the failure to use exposed and
un infected patients as controls, because it was too difficult
to get the negative spouses of the patients (though their
number was very small) due to various reasons, although
some of the control individuals used in the study had
reported experiencing of promiscuous sexual behavior
[41].
Apart from the nucleotide excision repair role of
ERCC2, this gene is linked with other roles like viral DNA
degradation, basal transcription repair complex FIIH and
p53 mediated regulator of apoptosis which could have
effect on viral host interactions [42].
Retroviral DNA integration creates a discontinuity in the
host cell chromatin and repair of this damage is required to
complete the integration process. As integration and repair
are essential for both viral replication and cell survival, it is
possible that specific interactions with the host DNA repair
systems might provide new cellular targets for human
immunodeficiency virus therapy [43, 44]. One possible
way of accomplishing this target effectively is through
analyzing the role of host genetic factor in HIV disease
susceptibility and progression.
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